Cellectis - CLLS STOCK NEWS

Cellectis, a clinical-stage biotechnology company, announced key information regarding its share structure as of March 31, 2023. The total number of shares in capital stands at 55,583,768, while the total number of voting rights is 61,504,923. Cellectis focuses on innovative gene editing technologies, specifically TALEN and PulseAgile, to develop advanced cell and gene therapies aimed at treating cancers such as acute myeloid leukemia and multiple myeloma. The company operates under two primary platforms: UCART for CAR-T immunotherapies and .HEAL for hemopoietic stem cell therapies. Cellectis is listed on Nasdaq (CLLS) and Euronext Growth (ALCLS), with headquarters in Paris and additional locations in New York and Raleigh.

Cellectis, a leading clinical-stage biotechnology company, announced significant progress in its BALLI-01 clinical study evaluating UCART22, the most advanced allogeneic CAR T-cell product for relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). The first patient in Europe has been dosed in France after completing the 28-day Dose Limiting Toxicity period. This milestone underscores Cellectis' commitment to developing off-the-shelf therapies for patients who have not responded to other treatments. UCART22 targets the CD22 antigen, aiming to provide new therapeutic options. With proprietary GMP manufacturing facilities in Raleigh and Paris, Cellectis maintains control over production timelines, enhancing patient treatment prospects. Positive preliminary clinical data was shared in December 2022, supporting the continued administration of UCART22 post FCA lymphodepletion.

Calyxt, Inc. (Nasdaq: CLXT) announced it will execute a 1-for-10 reverse stock split effective after trading on April 24, 2023. This decision follows shareholder approval on June 1, 2022, and will reduce the number of outstanding shares from approximately 49.3 million to 4.9 million, with the adjusted common stock trading from April 25, 2023. The reverse stock split will not affect the total shares authorized or the par value. Adjustments will be made to equity-based awards, with fractional shares rounding up to whole shares. The common stock will continue trading under the symbol 'CLXT' but under a new CUSIP number. Further details are available in the definitive proxy statement filed with the SEC on April 19, 2022.

Cellectis has announced the entry into a warrant agreement and the drawdown of the first tranche of €20 million under a credit facility with the European Investment Bank (EIB). This funding, part of a larger €40 million facility, will support the development of Cellectis’ allogeneic CAR T-cell therapeutic pipeline, including UCART22 and UCART123. The first tranche's disbursement is contingent upon the issuance of warrants and the achievement of clinical milestones, both of which have been met. The warrants issued represent 5% of the company's outstanding shares at an exercise price of €1.92. The agreement includes customary negative covenants, and the total amount will mature in six years.

Cellectis, a clinical-stage biotechnology company, announced important data on its share capital as of February 28, 2023. The total number of shares in capital stands at 55,583,768, while the total number of voting rights is 61,651,088. Cellectis focuses on developing cell and gene therapies using its gene-editing platform, TALEN®, and aims to address significant medical needs in oncology and blood disorders. The company's innovative approaches include off-the-shelf CAR-T treatments. Cellectis is traded on both the Nasdaq Global Market under the ticker CLLS and Euronext Growth as ALCLS.

Cellectis, a clinical-stage biotechnology firm, announced the presentation of preclinical data on its UCARTMUC1 CAR T-cell therapy aimed at treating triple-negative breast cancer during the AACR Annual Meeting on April 14-19, 2023. The company is leveraging its advanced TALEN gene-editing technology to armor CAR T-cells, enhancing their efficacy against tumor microenvironments. This therapy targets the MUC1 antigen, which is overexpressed in many TNBC cases. Dr. Laurent Poirot expressed confidence in the product candidate's potential to address significant medical needs amidst challenges posed by solid tumors.

Cellectis has announced significant developments including a €40 million credit facility from the European Investment Bank and a follow-on equity offering of approximately $25 million to enhance its research and development efforts. Positive preliminary clinical data from the Phase 1 BALLI-01 trial of UCART22 for r/r B-cell ALL showed 60% of patients experienced anti-tumor activity. Additionally, the AMELI-01 trial for UCART123 in patients with r/r AML reported a 25% meaningful response rate. The company maintains a cash position of $95 million as of December 31, 2022, enabling sustained operational funding through 2024.

Cellectis S.A. (NASDAQ: CLLS) reported that its 49.1% subsidiary, Calyxt, Inc. (NASDAQ: CLXT), announced its Q4 2022 financial results. Calyxt plans to merge with Cibus Global in an all-stock transaction, expected to close in Q2 2023. Calyxt's revenue in Q4 2022 was negligible, down from $1.9 million in Q4 2021, mainly due to the wind-down of its soybean product line. Operating expenses decreased to $3.4 million from $6.6 million year-over-year. Calyxt's cash position was $3.5 million, and with interim funding from Cibus, it will sustain operations through Q2 2023. The merger aims to enhance synergies and innovation in agricultural gene editing.

Calyxt announced a merger with Cibus Global, aiming to create a leading company in gene editing for agriculture. The all-stock transaction allows Calyxt shareholders to retain approximately 5% ownership post-merger, expected to close in Q2 2023, pending shareholder approval. Financial results for Q4 2022 show nominal revenue of $0, down from $1.9 million in Q4 2021, primarily due to the cessation of the soybean product line, while operating expenses decreased to $3.4 million. Notably, Calyxt has secured interim funding from Cibus to sustain operations through Q2 2023. The company continues to progress on key customer projects and technologies.